Professor Dario Campana’s research strives to improve prognostication and monitoring of haematologic malignancies, as well as to develop novel and practical approaches to enhance the anti-cancer activity of immune cells. Achievements include the development of effective methods for monitoring residual disease in acute leukemia leading to high cure rates in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), the discovery of early T-cell precursor ALL (a subset of ALL with poor response to therapy), the development of the first anti-CD19-41BB-CD3 zeta chimeric antigen receptor, as well as of other methods to activate and genetically modify immune cells currently in clinical trials.
Prof Campana was Lecturer in Immunology at the Royal Free Hospital, University of London (UK) before moving to St. Jude Children's Research Hospital in Memphis. When he left for Singapore in July 2011, he was Vice Chair for Laboratory Research in the Department of Oncology, Full Member in the Departments of Oncology and Pathology, and Professor of Paediatrics at the University of Tennessee. He is the scientific founder of two biotechnology companies.
His special interests are in classification, prognostication and monitoring of acute leukaemia and cell therapy of cancer.
Grants:
As Principle Investigator
- STaR Award – Cell therapy of Cancer
- 2005 – 2007: Study on the paediatric prevalence of adverse drug reaction and allergy in Singapore